Aradigm Co. (NASDAQ:ARDM) has been given a consensus broker rating score of 0.00 () from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Brokers have set a 12-month consensus price objective of $26.00 for the company, according to Zacks. Zacks has also given Aradigm an industry rank of 96 out of 265 based on the ratings given to related companies.
Aradigm (NASDAQ:ARDM) opened at 1.77 on Tuesday. The stock’s market cap is $26.17 million. The firm’s 50-day moving average is $1.94 and its 200-day moving average is $3.59. Aradigm has a 12 month low of $1.47 and a 12 month high of $7.19.
An institutional investor recently bought a new position in Aradigm stock. Paulson & CO. Inc. purchased a new position in Aradigm Co. (NASDAQ:ARDM) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 192,727 shares of the company’s stock, valued at approximately $308,000. Paulson & CO. Inc. owned approximately 1.30% of Aradigm at the end of the most recent reporting period. Hedge funds and other institutional investors own 43.59% of the company’s stock.
Your IP Address:
Aradigm Company Profile
Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aradigm Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Co. and related companies with MarketBeat.com's FREE daily email newsletter.